Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review

OBJECTIVE: To assess the quality of reporting of adverse events in clinical trials of covid-19 drugs based on the CONSORT (Consolidated Standards of Reporting Trials) harms extension and according to clinical trial design, and to examine reporting of serious adverse events in drug trials published o...

Descripción completa

Detalles Bibliográficos
Autores principales: Madi, Karima, Flumian, Clara, Olivier, Pascale, Sommet, Agnès, Montastruc, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537984/
https://www.ncbi.nlm.nih.gov/pubmed/37779893
http://dx.doi.org/10.1136/bmjmed-2022-000352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537984/
https://www.ncbi.nlm.nih.gov/pubmed/37779893
http://dx.doi.org/10.1136/bmjmed-2022-000352

Ejemplares similares